Roth Capital Predicts Increased Earnings for GeoVax Labs

GeoVax Labs, Inc. (NASDAQ:GOVX) – Investment analysts at Roth Capital boosted their FY2024 earnings estimates for shares of GeoVax Labs in a research report issued to clients and investors on Tuesday, November 12th. Roth Capital analyst J. Aschoff now forecasts that the company will post earnings of ($4.30) per share for the year, up from their previous forecast of ($5.52). The consensus estimate for GeoVax Labs’ current full-year earnings is ($5.10) per share. Roth Capital also issued estimates for GeoVax Labs’ Q4 2024 earnings at ($0.60) EPS, FY2025 earnings at ($0.97) EPS, FY2026 earnings at ($0.87) EPS, FY2027 earnings at $0.25 EPS and FY2028 earnings at $8.55 EPS.

Other analysts have also issued research reports about the company. Alliance Global Partners initiated coverage on GeoVax Labs in a research note on Monday, November 11th. They issued a “buy” rating and a $15.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 target price on shares of GeoVax Labs in a report on Friday. Noble Financial increased their target price on shares of GeoVax Labs from $6.00 to $10.00 and gave the stock an “outperform” rating in a research report on Monday, August 19th. Finally, EF Hutton Acquisition Co. I raised shares of GeoVax Labs to a “strong-buy” rating in a research note on Tuesday, July 23rd. Four investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $13.25.

GeoVax Labs Trading Down 6.9 %

GOVX stock opened at $2.43 on Friday. GeoVax Labs has a 1-year low of $1.09 and a 1-year high of $11.18. The business’s 50 day moving average is $2.39 and its 200-day moving average is $2.59.

GeoVax Labs (NASDAQ:GOVX) last posted its earnings results on Tuesday, November 12th. The company reported ($0.91) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.29) by $0.38. The business had revenue of $2.79 million during the quarter, compared to the consensus estimate of $1.84 million. During the same period in the previous year, the firm earned ($4.80) EPS.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.